Bio-Technology General Corp. (BTG) announced that its growthhormone has been launched in Japan by its licensee, JCRPharmaceuticals Co. Ltd.
JCR also signed a marketing agreement with Nikken ChemicalsCo. Ltd. Both companies have launched Growject Injectable 4 IUin Japan.
BTG of New York shipped an initial order of $1.25 million bulkhuman growth hormone last month.
The Japanese growth hormone market is approaching $300million in annual sales, said Sim Fass, president and chiefexecutive officer of BTG (NASDAQ:BTGC).
(c) 1997 American Health Consultants. All rights reserved.